PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2013 | 85 | 9 | 544-562
Tytuł artykułu

Polish Consensus on Treatment of Gastric Cancer; Update 2013

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
Słowa kluczowe
Wydawca

Rocznik
Tom
85
Numer
9
Strony
544-562
Opis fizyczny
Daty
wydano
2013-09-01
online
2013-10-15
Twórcy
autor
  • 1st Chair of General Surgery and Clinic of General Surgery, Oncological Surgery and Gastroenterological Surgery, Jagiellonian University Medical College in Cracow
  • 2nd Chair and Clinic of General, Gastroenterogical and Gastrointestinal Cancer Surgery, Medical University in Lublin
  • Chair and Clinic of General Surgery, Gastroenterological Surgery and Plastic Surgery, Medical University in Poznań
  • Chair and Clinic of General, Transplantation and Liver Surgery, Warsaw Medical University
  • Clinic of Oncological Surgery, Medical Uniuversity in Łódź
  • 2nd Chair and Clinic of General Surgery and Oncological Surgery, Medical University in Wrocław
  • 1st Chair of General Surgery and Clinic of General Surgery, Oncological Surgery and Gastroenterological Surgery, Jagiellonian University Medical College in Cracow
  • Department of Anatomical Pathology, Central Clinical Hospital of the Ministry of Interior in Warsaw
  • Department of Anatomical Pathology, Faculty of Health Sciences, Jan Kochanowski University in Kielce
  • Chair and Clinic of Gastroenterology, Pomeranian Medical University in Szczecin
  • 2nd Chair and Clinic of General, Gastroenterogical and Gastrointestinal Cancer Surgery, Medical University in Lublin
  • Chair and Clinic of General, Transplantation and Liver Surgery, Warsaw Medical University
Bibliografia
  • 1. Edge SB , Byrd DR, Compton CC I et al.: AJCC Cancer Staging Manual. 7th ed. New York - Dordrecht - Heidelberg - London: Springer, 2010.
  • 2. Greene FL, Page DI et al.: AJCC Cancer Staging Manual. 6th ed. New York: Springer Verlag, 2002.
  • 3. McGhan LJ, Pockaj BA , Gray RJ et al.: Validation of the Updated 7th Edition AJCC TNM Staging Criteria for Gastric Adenocarcinoma. J Gastrointestsurg 2012; 16: 53-61.[Crossref]
  • 4. Nasierowska-Guttmejer A, Majewski P, MalinowskaM: Czynniki prognostyczne i predykcyjne w raku żołądka. Pol J Pathol 2013; supl 1 (w przygotowaniu do druku).
  • 5. Lauwers GY, Carneiro F, Graham DY et al.: (2010) Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO Classification of tumours of the digestive system, 4th edn. IARC, Lyon, 48-58.
  • 6. Dinis-Ribeiro M, Areia M, de Vries AC et al.: Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Society of Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de EndoscopiaDigestiva (SPED). Virchows Arch 2012; 460: 19-46.
  • 7. Okines A, Verheij M, Allum W et al.: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up On behalf of the ESMO Guidelines Working Group. Ann Oncol 2010; 21 (Supplement 5): v50-v54.[Crossref]
  • 8. Fujishiro M: Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms. World J Gastroenterol 2008; 14: 4289-95.[PubMed][Crossref]
  • 10. Akahoshi K, Akahane H: A new breakthrough: ESD using a newly developed grasping type scissor forceps for early gastrointestinal tract neoplasms. World J Gastrointest Endosc 2010; 16: 90-96.[Crossref]
  • 11. Probst A, Pommer B, Golger D et al.: Endoscopic submucosal dissection in gastric neoplasia - experience from a European center Endoscopy 2010; 42: 1037-44.[PubMed][Crossref]
  • 12. Sano T, Aiko T: The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011. Gastric Cancer Treatment Guidelines 2010, version 3. New Japanese classification and treatment guidelines for gastric cancer: revision concepts and major revised points. GastricCancer 2011; 14: 97-100.[Crossref]
  • 13. Washington K: 7th Edition of the AJCC Cancer Staging Manual: Stomach. Ann Surg Oncol 2010; 17: 3077-79.[Crossref]
  • 14. Lauren P: The two histological main types of gastrin carcinoma: diffuse and so-called intestinaltype carcinoma. An attempt at a histo-clinical classification. Microbiol Scand 1965; 64: 31-49.
  • 15. Olszewski WP, Olszewski WT : Rola patomorfologa w doborze terapii ukierunkowanej na receptor czynnika wzrostu naskórka (EGFR) u chorych na nowotwory. Onkol Prak Klin 2010; 6: 228-35.
  • 16. Hofmann M, Stoss O, Shi D et al.: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805.[Crossref]
  • 17. Ruschoff J, Dietel M, Baretton G et al.: HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunochistochemical testing. Virchov Arch 2010; 457: 2999-2307.
  • 18. Ruschoff J, Wedad H, Michael B et al.: HER2 testing in gastric cancer: a practical approach. Modern Pathology 2012; 1-14.
  • 19. Gospodarowicz M, WittekindCh, Sobin L & International Union Against Cancer TNM 7th edition. Gastric cancer. (2010). www.uicc.org
  • 20. Dikken JL, (van de Velde CJ), The New AJCC / IUAC staging system for adenocarcionoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol 2012; 19: 2443-51.[Crossref]
  • 21. Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br JSurg 1998; 85: 1457-59.
  • 22. Bhandari P, Green S, Hamanaka H et al.: Use of Gascon and Pronase either as a pre-endoscopic drink or as targeted endoscopic flushes to improve visibility during gastroscopy: a prospective, randomized, controlled, blinded trial. Scand J Gastroenterol 2010; 45: 357-61.[Crossref][PubMed]
  • 23. Kato M, Kaise M, Yonezawa J et al.: Magnifying endoscopy with narrow -band imaging achieves superior accuracy in the differential diagnosis of superficial gastric lesions identified with white-light endoscopy: a prospective study. GastrointestEndosc 2010; 72: 523.
  • 24. Chai N-L, Ling-Hu E-Q, Morita Y et al.: Magnifying endoscopy in upper gastroenterology for assessing lesions before completing endoscopic removal. World J Gastroenterol 2012; 18: 1295-1307.[Crossref]
  • 25.Yan LH, mmed DJ, Han-Bing X et al.: Application of magnifying endoscopy with narrow-band imaging in diagnosing gastric lesions: a prospective study. Gastrointest Endosc 2012 (in press).
  • 26. Ang TL, Khor CJ, Gotoda T: Diagnosis and endoscopic resection of early gastric cancer. SingaporeMed J 2010; 51: 93-100.[PubMed]
  • 27. Dumonceau J-M, Polkowski M, Larghi A et al.: Indications, results, and clinical impact of endosopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2011; 43: 897-909.
  • 28. Lutz MP, Zalcberg JR, Ducreux M et al.: Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and esophageal cancer. EurJ Cancer 2012; 48, 2941-53.[Crossref]
  • 29. Cardoso R, Coburn N, Seevaratnam R et al.: A systemic review and metaanalysis of the utility of EUS for preoperative staging for gastric cancer. Gastric Cancer 2012; 15 Supp1: S19-26.[Crossref]
  • 30. Lee HH, Lee S-Y, Yoon HY et al.: Change of mucosal color in early gastric cancer. J Dig Diseases 2012; 13: 510-16.[Crossref]
  • 31. Siewert JR, Böttcher K, Roder JD et al.: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg 1993; 80(8): 1015-18.[Crossref]
  • 32. Roukos DH, Paraschou P, Lorenz M: Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. AnnSurg Oncol 2000; 7(10): 719-26.
  • 33. Piso P, Werner U, Lang H et al.: Proximal versus distal gastric carcinoma-what are the differences? Ann Surg Oncol 2000; 7(7): 520-25.[Crossref][PubMed]
  • 34. Bozzetti F, Marubini E, Bonfanti G et al.: Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230(2): 170-78.[Crossref]
  • 35. Sano T, Kodera Y: The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 101-12.
  • 36. Sano T, Kodera Y: The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2011. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23.
  • 37. Sasson AR et al.: NCCN Clinical Practice Guidelines in Oncology. (National Comprehensive Cancer Network, version 2.2012). Gastric Cancer NCCN Guidelines - including cancer in the proximal 5 cm of the stomach. www. nccn.org
  • 38. Sasako M, Sano T, Yamamoto S et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359(5): 453-56.
  • 39. Zhen Wang, Jun-Qiang Chen et al.: Systematic review of D2 lymphadenectomy versus D2 with para-aortic nodal dissection for advanced gastric cancer. Worl J Gastroenterol 2010; 16: 1138-49.
  • 40. Kulig J, Popiela T, Kolodziejczyk P, Sierzega M on behalf of the Polish Gastric Cancer Study Group. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193(1): 10-15.[Crossref]
  • 41. Sano T, Yamamoto S, Sasako M. Japan Clinical Oncology Group Study LCOG 0110-MF. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. JpnJ Clin Oncol 2002; 32(9): 363-64.[Crossref]
  • 42. Sasako M, Sano T, Yamamoto S (JCOG9502) et al.: Left thoracoabdominal approach versus abdominal- transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 2006, 7(8): 644-51.
  • 43. Hiroshi O, Yutaka T, Kozo N et al.: A Meta- Analysis of Randomized Controlled Trials that Compared Laparoscopy-Assisted and Open Distal Gastrectomy for Early Gastric Cancer. J GastrointestSurg 2010; 14: 958-64.
  • 44. Byung Hee Kang, Yi Xuan, Hoon Hur et al.: Comparison of Surgical Outcomes between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: The Learning Curve of Robotic Surgery. J GastricCancer 2012; 12(3): 156-63.
  • 45. Yang HK, Suh YS , Lee HJ: Minimally invasive approaches for gastric cancer-Korean experience. J Surg Oncol 2012; 17.
  • 46. Rausei S, Dionigi S, Rovera F: A decade in gastric cancer curative surgery: Evidence of progress (1999-2009). World J Gastrointest Surg 2012; 4(3): 45-54.
  • 47. Saka M, Morita S, Fukagawa T, Katai H: Present and Future Status of Gastric Cancer Surgery. Jpn J Clin Oncol 2011; 41(3): 307-13.[Crossref][PubMed]
  • 48. Alonso-Lárraga JO, Alvaro-Villegas JC, Sobrino-Cossío S et al.: Self-expanding metal stents versus antrectomy for the palliative treatment of obstructive adenocarcinoma of the gastric antrum. Rev Esp Enferm Dig 2012; 104(4): 185-89.[Crossref]
  • 49. Meyer H, Wilke, H: Treatment Strategies in Gastric Cancer. Dtsch Arztebl Int 2011; 108(41): 698-706.[PubMed]
  • 50. Kakeji Y, Morita M, Maehara Y: Strategies for treating liver metastasis from gastric cancer. SurgToday 2010; 40(4): 287-94.
  • 51. Cunningham D, Allum WH, Stenning SP et al.: and MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Eng J Med 2006 6; 355(1): 11-20.
  • 52. Ychou M, Boige V, Pignon JP et al.: Perioperative chemotherapy compared with surgery alone for resectablegastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 1: 29.[Crossref]
  • 53. Smalley SR , Benedetti JK, Haller DG et al.: SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. JClin Oncol 2012; 30(19): 2327-33.[Crossref]
  • 54. Cunningham D, Starling N, Rao S et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.[Crossref]
  • 55. Kang YK , Kang WK , Shin DB et al.: Capecitabine/ cisplatin versus 5-fluorouracil/ cisplatin as first-line therapy in patients with advanced gastric cancer: arandomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-73.[Crossref]
  • 56. Okines AF, Norman AR , McCloud P et al.: Metaanalysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophagogastric cancer. Ann Oncol 2009; 20: 1529-34.
  • 57. Van Cutsem E, Chung H, Shen L: Efficacy results from the ToGA trial: A phase III stduy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) In ASCO Annual Meeting, Orlando, FL, USA. JClin Oncol 2009; LBA4509.
  • 58. Thuss-Patience PC, Deist T, Hinke A: Irinotecan versus best supportive care (BSC) as secondline therapy in gastric cancer: a randomized phase III study of the ArbeitsgemeinschaftInternistischeOnkologie (AIO) In ASCO Annual Meeting, Orlando, FL, USA. J Clin Oncol 2009; Abstr 4540.
  • 59. Dank M, Zaluski J, Barone C et al.: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19: 1450-57.[Crossref]
  • 60. Kulig J, Kołodziejczyk P, Kulig P, Legutko J: Targeted therapy for gastric cancer - current status. Oncol Pharm Practice 19(1) 75-81.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_pjs-2013-0083
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.